7Baggers
Quarterly
Annual
    Unit: USD2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2011-03-31 2010-06-30 2010-03-31 2009-09-30 2009-06-30 
      
    		                                       
      assets
    		                                       
      investments, at fair value:
    		                                       
      non-control/non-affiliate investments
    		3,546,799,000 3,546,799,000 3,457,280,000 3,459,426,000 3,133,042,000 3,133,042,000 2,385,998,000 2,288,338 2,355,935,000 2,297,180,000 2,238,479,000 2,232,972 2,167,682,000 2,174,691,000 2,003,062,000 1,801,258,000 1,670,034,000 1,616,515,000 1,398,640,000 1,491,458 1,360,146,000 1,357,914,000 1,376,181,000 1,414,210 1,309,696,000 1,292,934,000   1,142,544,000 1,228,202,000 1,150,639,000 1,012,738 990,068,000 983,952,000 443,022,000 390,399,000 332,728,000   
      control investments
    		113,179,000 113,179,000 111,259,000 112,215,000 115,004,000 115,004,000 68,693,000 57,400 55,092,000 54,431,000 51,775,000 59,746 58,560,000 55,894,000 54,913,000 57,619,000 62,387,000 56,716,000 54,413,000 19,461 23,382,000 31,564,000 24,775,000 4,700 4,991,000 4,000,000          37,904,000 45,023,000   
      total investments, at fair value
    		3,659,978,000 3,659,978,000 3,568,539,000 3,571,641,000 3,248,046,000 3,248,046,000 2,464,355,000 2,354,078                                
      cash and cash equivalents
    		42,679,000 42,679,000 27,676,000 50,176,000 98,899,000 98,899,000 74,987,000 198,282 27,554,000 35,884,000 34,282,000 64,393 21,045,000 13,261,000 16,465,000 34,212,000 43,212,000 59,461,000 118,228,000 91,309 140,568,000 160,412,000 148,140,000 13,044 69,012,000 59,715,000 13,478,000 95,196 147,304,000 115,987,000 171,756,000 227,116 158,627,000 116,008,000 114,435,000 52,751,000 106,138,000 77,247,000 37,367,000 
      foreign cash
    		70,445,000 70,445,000                                      
      restricted cash
    		3,297,000 3,297,000 11,242,000 10,110,000 17,114,000 17,114,000 11,829,000 39,340 20,507,000 33,599,000 22,060,000 50,603 14,886,000 15,339,000 10,149,000 11,645,000 2,429,000 15,886,000 3,632,000 3,686 7,813,000 17,226,000 12,924,000 8,322 8,980,000 3,605,000 3,646,000 9,191 5,358,000 11,810,000 21,949,000 12,660 2,096,000 3,491,000      
      interest receivable
    		32,578,000 32,578,000 31,533,000 35,399,000 32,741,000 32,741,000 20,597,000 19,077 19,506,000 19,458,000 19,137,000 20,207 19,847,000 18,206,000 18,366,000 16,959,000 15,722,000 14,408,000 11,087,000 12,262 10,507,000 10,204,000 11,484,000 11,614 10,861,000 9,453,000 10,993,000 9,239 8,528,000 9,226,000 9,102,000 9,453 9,146,000 8,700,000 4,306,000 11,114,000 11,369,000 10,382,000 9,327,000 
      right of use asset
    		16,778,000 16,778,000 18,104,000 18,579,000 4,787,000 4,787,000 8,666,000 9,278 9,884,000 10,492,000 11,078,000 11,659 12,218,000 8,493,000 8,856,000                         
      other assets
    		5,836,000 5,836,000 15,042,000 10,128,000 15,339,000 15,339,000 3,417,000 3,942 5,723,000 5,547,000 7,714,000 580 1,727,000 4,269,000 3,753,000 2,002,000 1,175,000 906,000 3,187,000 5,244 6,995,000 5,398,000 7,433,000 7,282 9,961,000 19,620,000 12,388,000 20,497 19,813,000 20,875,000 22,860,000 29,257 30,556,000 29,929,000 10,611,000 6,948,000 6,687,000 5,851,000 7,085,000 
      total assets
    		3,831,591,000 3,831,591,000 3,672,136,000 3,696,033,000 3,416,926,000 3,416,926,000 2,583,851,000 2,623,997 2,504,001,000 2,468,501,000 2,396,751,000 2,461,968 2,316,929,000 2,311,567,000 2,138,631,000 1,945,191,000 1,823,054,000 1,792,597,000 1,619,712,000 1,654,715 1,582,997,000 1,588,709,000 1,586,248,000 1,464,204 1,419,424,000 1,395,171,000 1,331,815,000 1,334,761 1,332,731,000 1,396,553,000 1,387,088,000 1,299,223 1,199,338,000 1,149,473,000 574,406,000 497,441,000 500,957,000 505,120,000 501,895,000 
      liabilities
    		                                       
      debt
    		1,768,955,000 1,768,955,000 1,747,127,000 1,751,998,000 1,554,869,000 1,554,869,000 1,231,298,000                                 
      accounts payable and accrued liabilities
    		54,861,000 54,861,000 49,519,000 38,698,000 54,156,000 54,156,000 28,300,000 36,343 28,782,000 29,162,000 22,450,000 30,306 25,451,000 27,274,000 18,256,000 25,961,000 21,473,000 25,115,000 18,789,000 26,896 19,057,000 22,193,000 16,513,000 21,463 16,649,000 16,681,000 12,086,000 17,241 19,613,000 12,977,000 9,320,000 14,101 11,613,000 10,393,000 7,449,000 7,658,000 3,945,000 5,798,000 6,645,000 
      operating lease liability
    		18,194,000 18,194,000 18,945,000 19,399,000 5,195,000 5,195,000 8,859,000 9,312 9,753,000 10,178,000 11,144,000 11,538 11,922,000 8,530,000 8,856,000                         
      total liabilities
    		1,842,010,000 1,842,010,000 1,815,591,000 1,810,095,000 1,614,220,000 1,614,220,000 1,268,457,000 1,332,293 1,330,921,000 1,304,471,000 1,299,671,000 1,328,919 1,231,248,000 1,206,883,000 1,148,282,000 989,747,000 818,874,000 828,900,000 790,981,000 813,748 746,713,000 771,258,000 778,352,000 676,260 665,835,000 677,376,000 613,435,000 617,627 609,938,000 652,862,000 623,762,000 640,359 543,140,000 490,564,000 171,199,000 144,758,000 134,545,000 136,398,000 137,662,000 
      commitments and contingencies
    		                                       
      net assets consist of:
    		                                       
      common stock
    		171,000 171,000 163,000 163,000 158,000 158,000 116,000 115 115,000 115,000 111,000 108 105,000 104,000 96,000 96,000 96,000 94,000 85,000 85 84,000 83,000 83,000 80 77,000 75,000 74,000 73 73,000 73,000 73,000 65 65,000 64,000 43,000 36,000 35,000 35,000 35,000 
      capital in excess of par value
    		1,900,490,000 1,900,490,000 1,737,478,000 1,730,829,000 1,662,535,000 1,662,535,000 1,160,519,000 1,158,198 1,225,823,000 1,223,263,000 1,182,080,000 1,145,106 1,147,054,000 1,149,774,000 1,051,427,000 1,052,269,000 1,060,875,000 1,026,313,000 916,738,000 908,501 904,357,000 892,930,000 890,861,000 839,657 802,521,000 774,339,000 761,565,000 752,244 757,646,000 760,148,000 760,034,000 657,233 670,711,000 668,673,000 478,959,000 408,502,000 410,349,000 408,733,000 407,300,000 
      total distributable earnings
    		88,920,000 88,920,000 118,904,000 154,946,000 140,013,000 140,013,000 154,759,000 133,391 -52,858,000 -59,348,000 -85,111,000 -12,165 -61,478,000 -45,194,000 -61,174,000 -92,859,000                        
      total net assets
    		1,989,581,000 1,989,581,000 1,856,545,000 1,885,938,000 1,802,706,000 1,802,706,000 1,315,394,000 1,291,704 1,173,080,000 1,164,030,000 1,097,080,000 1,133,049 1,085,681,000 1,104,684,000 990,349,000 955,444,000 1,004,180,000 963,697,000 828,731,000 840,967 836,284,000 817,451,000 807,896,000 787,944 753,589,000 717,795,000 718,380,000 717,134 722,793,000 743,691,000 763,326,000 658,864 656,198,000 658,909,000 403,207,000 352,683,000 366,412,000 368,722,000 364,233,000 
      total liabilities and net assets
    		3,831,591,000 3,831,591,000 3,672,136,000 3,696,033,000 3,416,926,000 3,416,926,000 2,583,851,000 2,623,997 2,504,001,000 2,468,501,000 2,396,751,000 2,461,968 2,316,929,000 2,311,567,000 2,138,631,000 1,945,191,000 1,823,054,000 1,792,597,000 1,619,712,000 1,654,715 1,582,997,000 1,588,709,000 1,586,248,000 1,464,204 1,419,424,000 1,395,171,000 1,331,815,000 1,334,761 1,332,731,000 1,396,553,000 1,387,088,000 1,299,223 1,199,338,000 1,149,473,000 574,406,000     
      shares of common stock outstanding
    		170,575,000 170,575,000 162,428,000 162,230,000 157,758,000 157,758,000 115,768,000 114,726 114,317,000 114,230,000 110,601,000 107,364 104,636,000 104,282,000 96,543,000 96,501,000 96,751,000 94,260,000 85,239,000 84,424 83,615,000 82,819,000 82,801,000 79,555 76,400,000 74,320,000 73,230,000 72,118 72,109,000 72,493,000 72,891,000 64,715 64,182,000 63,251,000 43,804,000 35,972,000 36,248,000 35,546,000 35,452,000 
      net asset value per share
    		11,660 11,660 11,430 11,630 11,430 11,430 11,360 11.26 10,260 10,190 9,920 10.55 10,380 10,590 10,260 9,900 10,380 10,220 9,720 9.96 10,000 9,870 9,760 9.9 9,860 9,660 9,810 9.94 10,020 10,260 10,470 10.18 10,220 10,420 9,200 9,800 10,110 10,370 10,270 
      affiliate investments
    		      9,664,000 8,340 9,800,000 11,910,000 12,226,000 21,808 20,964,000 21,414,000 23,067,000 21,496,000 28,095,000 28,705,000 30,525,000 31,295 33,586,000 5,991,000 5,311,000 5,032 5,923,000 5,844,000   9,184,000 10,453,000 10,782,000 7,999 8,845,000 7,393,000 2,032,000 3,218,000 2,222,000 4,280,000 1,133,000 
      2027 asset-backed notes, investments in securities, at value
    		      235,476,000                                 
      2028 asset-backed notes, investments in securities, at value
    		      340,620,000                                 
      2027 asset-backed notes
    		      130,016,000 178,812 197,521,000 197,448,000 197,377,000 197,312 197,241,000 197,171,000 197,102,000 197,265,000                        
      2028 asset-backed notes
    		      219,413,000 247,647 247,579,000 247,511,000 247,444,000 247,395 247,333,000 247,266,000 247,352,000                         
      sba debentures
    		       98,716 98,668,000 109,808,000 109,725,000 148,165 148,038,000 147,910,000 147,783,000 147,655,000 147,527,000 188,457,000 188,299,000 188,141 187,983,000 187,824,000 187,669,000                 
      2022 notes
    		       149,039 148,907,000 148,776,000 148,645,000 148,514 148,383,000 148,252,000 148,121,000 147,990,000 147,859,000 147,728,000 147,698,000 147,572                    
      july 2024 notes
    		       103,942 103,869,000 103,795,000 103,721,000 103,685 103,723,000                           
      february 2025 notes
    		       49,522 49,493,000 49,465,000 49,442,000                             
      april 2025 notes
    		       73,351                                
      june 2025 notes
    		       69,272 69,233,000 69,217,000                              
      march 2026 a notes
    		       49,550                                
      2033 notes
    		       38,610 38,582,000 38,555,000 38,528,000 38,501 38,474,000 38,447,000 38,420,000 38,427,000 38,752,000                       
      2022 convertible notes
    		       228,177 227,786,000 227,395,000 227,004,000 226,614 226,223,000 225,832,000 225,441,000 225,051,000 224,660,000 224,269,000 223,878,000                     
      credit facilities
    		        37,492,000  71,125,000 103,919 11,585,000 93,421,000 44,266,000 52,956,000 80,894,000 58,323,000      5,016                
      investments:
    		                                       
      total investments in securities, at value
    		        2,420,827,000 2,363,521,000 2,302,480,000 2,314,526 2,247,206,000 2,251,999,000 2,081,042,000 1,880,373,000 1,760,516,000 1,701,936,000 1,483,578,000 1,542,214 1,417,114,000                   
      2025 notes
    		        73,256,000 73,161,000 73,066,000 72,970 72,875,000 72,780,000 72,685,000 72,590,000 72,495,000 72,616,000                      
      2024 notes
    		               81,852,000 81,791,000 81,694,000 179,161,000 179,001 251,716,000 251,478,000 251,240,000 245,490 237,663,000 237,570,000 100,211,000 103,000 103,000,000 103,000,000 103,000,000 103,000 103,000,000       
      treasury stock
    		               -4,062,000                        
      2021 asset-backed notes
    		                3,423,000 30,698,000 33,156,000 48,650 64,860,000 86,865,000 100,388,000 107,972 115,531,000 127,461,000 127,227,000 129,300 129,300,000 129,300,000 129,300,000 129,300        
      unrealized appreciation (depreciation) on investments
    		                -53,784,000 -56,760,000              -17,076 -14,706,000 -5,224,000  -25,141,000 -10,288,000  -37,922,000 
      accumulated undistributed realized gains on investments
    		                -30,855,000 -34,205,000 -25,294,000 -20,374 10,674,000 35,128,000 40,840,000 37,603                
      undistributed net investment income
    		                27,848,000 28,255,000 32,159,000 32,515       -12,642,000 -10,368 -7,311,000 -8,429,000 -2,710,000 4,563 2,361,000 3,293,000      
      unrealized depreciation on investments
    		                  -94,957,000 -79,760 -73,388,000 -106,941,000 -120,528,000 -89,025 -68,880,000 -68,046,000 -54,142,000 -52,808 -50,118,000 -24,238,000 -11,462,000    -23,390,000   -20,405,000  
      convertible notes
    		                   223,488 223,097,000 222,898,000 222,542,000                 
      2019 notes
    		                       108,818 108,659,000 108,499,000 108,339,000 110,364 150,364,000 150,364,000 170,364,000 170,364 170,364,000 170,364,000      
      distributions in excess of net investment income
    		                    -5,443,000 -3,749,000 -3,360,000 -371 -11,549,000 -12,123,000              
      total investments, at value
    		                     1,395,469,000 1,406,267,000 1,423,942 1,320,610,000 1,302,778,000 1,291,310,000 1,200,638 1,151,728,000 1,238,655,000 1,161,421,000 1,020,737 998,913,000 991,345,000 445,054,000 431,521,000 379,973,000 414,847,000 452,390,000 
      long-term sba debentures
    		                       187,501 187,333,000 187,165,000 186,997,000 190,200 190,200,000 190,200,000 190,200,000 190,200 190,200,000 190,200,000 163,750,000 137,100,000 130,600,000 130,600,000 130,600,000 
      long-term liabilities
    		                          17,572,000 17,522 17,461,000 17,399,000 17,375,000 17,345 40,012,000 73,060,000      
      wells facility
    		                          61,003,000 50,000  49,622,000          
      accumulated realized gains on investments
    		                        31,420,000 23,550,000 23,525,000 27,993 22,503,000 16,137,000 17,391,000 14,079    -24,408,000 -27,767,000  -1,426,000 
      non-control/non-affiliate investments:
    		                                       
      debt investments
    		                          1,204,136,000 1,109,196            
      equity investments
    		                          55,837,000 60,781            
      warrant investments
    		                          23,240,000 22,675            
      total non-control/non-affiliate investments
    		                          1,283,213,000 1,192,652            
      affiliate investments:
    		                                       
      total affiliate investments
    		                          8,097,000 7,986            
      non-control/non affiliate investments:
    		                                       
      2017 asset-backed notes
    		                              4,203,000 16,049        
      amounts includes 1.9 million in net unrealized depreciation on investments, other assets, and accrued liabilities including escrow receivables, estimated taxes payable, and citigroup warrant participation agreement liabilities.
    		                                       
      asset-backed notes
    		                              133,503,000  27,951,000 46,547,000      
      accumulated realized losses on investments
    		                                -2,233,000 -7,897,000 -46,663,000     
      net assets:
    		                                       
      distributions in excess of investment income
    		                                  -5,742,000 -6,306,000 -5,917,000 -4,041,000 -3,754,000 
      portfolio company
    		                                       
      acceleron pharmaceuticals, inc.
    		                                       
      total acceleron pharmaceuticals, inc.
    		                                       
      anthera pharmaceuticals inc.
    		                                       
      total anthera pharmaceuticals inc.
    		                                       
      aveo pharmaceuticals, inc.
    		                                       
      total aveo pharmaceuticals, inc.
    		                                       
      dicerna pharmaceuticals, inc.
    		                                       
      total dicerna pharmaceuticals, inc.
    		                                       
      epicept corporation
    		                                       
      total epicept corporation
    		                                       
      horizon therapeutics, inc.
    		                                       
      total horizon therapeutics, inc.
    		                                       
      inotek pharmaceuticals corp.
    		                                       
      total inotek pharmaceuticals corp.
    		                                       
      merrimack pharmaceuticals, inc.
    		                                       
      total merrimack pharmaceuticals, inc.
    		                                       
      paratek pharmaceuticals, inc.
    		                                       
      total paratek pharmaceuticals, inc.
    		                                       
      deferred loan origination revenue
    		                                   -4,893,000 -3,210,000 -3,207,000 -4,274,000 
      net assets
    		                                   352,683,000 366,412,000 368,722,000 364,233,000 
      elixir pharmaceuticals, inc.
    		                                       
      total elixir pharmaceuticals, inc.
    		                                       
      epicept corporation.
    		                                       
      total epicept corporation.
    		                                       
      short-term credit facility
    		                                       
      non-affiliate investments
    		                                     410,567,000 451,257,000 
      accumulated realized gain on investments
    		                                     -15,600,000  
      portola pharmaceuticals, inc.
    		                                       
      total portola pharmaceuticals, inc.
    		                                       
      recoly, n.v.
    		                                       
      total recoly, n.v.
    		                                       
      total drug discovery
    		                                       
      long-term credit facility
    		                                      417,000 
      acceleron pharmaceuticals, inc.*
    		                                       
      affinity videonet, inc.
    		                                       
      total affinity videonet, inc.
    		                                       
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.